Loading organizations...
Key people at Immix Biopharma.
Immix Biopharma is a clinical-stage biopharmaceutical company based in Los Angeles, California, developing novel therapies for cancer and inflammatory diseases. The company leverages its proprietary SMARxT Platform technology to advance drug candidates through preclinical research and human clinical trials, building on groundbreaking cell therapy research in the emerging cell therapy space. Immix completed an Initial Public Offering (IPO) on Nasdaq (IMMX) in 2021, raising approximately $21.0 million to fund clinical development and operations. Key leadership includes CEO and Founder Ilya Rachman, a physician/scientist and world-renowned pharmacology expert, alongside COO and Co-Founder Vladimir Drozdoff, and CFO Gabriel Morris. Its board of directors features former senior members from Prometheus Biosciences, acquired by Merck. Immix Biopharma was founded in 2012 by Ilya Rachman and Vladimir Drozdoff.
Key people at Immix Biopharma.
Immix Biopharma (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company developing sterically-optimized CAR-T cell therapies, primarily targeting AL Amyloidosis and other serious diseases like immune-mediated conditions.[1][2][3] Its lead candidate, NXC-201—a BCMA-targeted CAR-T therapy—is in Phase 1b/2a trials (NEXICART-2 in the U.S. and NEXICART-1 ex-U.S.), showing zero neurotoxicity across 58 multiple myeloma patients and positive early outcomes in 13 AL Amyloidosis patients, addressing unmet needs in rare, life-threatening diseases with high patient impact potential.[2][3]
The company serves patients with relapsed/refractory AL Amyloidosis and expands to broader indications, solving key CAR-T limitations like neurotoxicity and CRS to enable wider adoption beyond specialized blood cancer centers.[1][3] Growth momentum includes Memorial Sloan Kettering Cancer Center as the lead U.S. trial site, a robust clinical dataset from 63 myeloma patients demonstrating tolerability at high doses, and platform expansion for multiple diseases.[2]
Immix Biopharma was founded in 2012 by a physician/scientist, a world-renowned pharmacology expert, a seasoned biotechnology patent expert, and an impact-driven leader, building on groundbreaking CAR-T research from pioneers like Dr. Carl June at the University of Pennsylvania and Dr. Renier Brentjens at Memorial Sloan Kettering in the early 2010s.[3] The idea emerged from the 2017 FDA approvals of first-generation CAR-T therapies (Kymriah and Yescarta) for blood cancers, highlighting a critical gap: severe neurotoxicity that limited use to ~5% of U.S. medical centers and certain indications.[3]
Early traction accelerated post-IPO with a NASDAQ listing in the second half of 2021, formation of an IMMX Cell Therapy R&D Task Force in early 2022, and identification/securing of global rights to NXC-201 in late 2022, backed by Phase 1 data showing no neurotoxicity and single-day CRS in high-dose multiple myeloma patients—pivotal for AL Amyloidosis entry.[3]
Immix Biopharma rides the CAR-T revolution in cell therapy, targeting AL Amyloidosis—a rare, fatal disease affecting ~4,000 new U.S. patients yearly with no curative options beyond stem cell transplants—while leveraging myeloma data for faster validation.[2][3] Timing is ideal amid post-2017 CAR-T approvals and growing demand for next-gen therapies that reduce toxicities, aligning with market forces like expanding cell therapy pipelines (oncology/immunology) and regulatory support for orphan indications.[1][5]
It influences the ecosystem by pioneering community-based CAR-T delivery, democratizing access beyond elite centers, and validating sterically-optimized tech for non-cancer diseases, potentially accelerating industry-wide adoption and investment in tolerable cell therapies.[3]
Immix is poised for NXC-201 readouts from multi-site AL Amyloidosis trials, potential regulatory milestones, and platform expansion to additional serious diseases, fueled by its unmatched tolerability data.[2] Trends like AI-optimized cell engineering, outpatient CAR-T, and orphan drug incentives will shape its path, amplifying influence as a tolerability leader in a market projected to grow with safer therapies. This positions Immix to redefine AL Amyloidosis care, echoing its founding mission to overcome CAR-T barriers for global patient impact.[1][3]
